title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Friday,20220506T160650,https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article,DARE,0.005467,Neutral,-0.05572
Stocks That Hit 52-Week Lows On Thursday,20220428T193101,https://www.benzinga.com/markets/options/22/04/26872967/52-weeks-high-and-low-article,DARE,0.00644,Neutral,-0.102936
"Earnings Scheduled For May 12, 2022",20220512T085523,https://www.benzinga.com/news/earnings/22/05/27156592/earnings-scheduled-for-may-12-2022,DARE,0.017681,Neutral,-0.07891
Stocks That Hit 52-Week Lows On Wednesday,20220504T162909,https://www.benzinga.com/markets/options/22/05/26995541/52-weeks-high-and-low-article,DARE,0.012359,Neutral,-0.038017
This overlooked corner of women's health could be a $350 billion market opportunity,20240315T183339,https://www.cnbc.com/2024/03/15/this-overlooked-corner-of-womens-health-could-be-a-350-billion-market-opportunity.html,DARE,0.0378,Neutral,0.056481
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities,20240813T113000,https://www.globenewswire.com/news-release/2024/08/13/2929086/7281/en/XOMA-Royalty-Reports-Second-Quarter-2024-Financial-Results-and-Highlights-Recent-Activities.html,DARE,0.025873,Somewhat-Bullish,0.169309
"The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More",20220512T124254,https://www.benzinga.com/general/biotech/22/05/27161064/the-daily-biotech-pulse-bristol-myers-bridgebio-ink-oncology-pact-fda-nod-for-lava-therapeutics-b,DARE,0.080525,Bearish,-0.382155
